By Amber Deter The MindMed IPO is making waves in the news. It will be the second psychedelics company to go public in the U.S. after the Compass Pathways (Nasdaq: CMPS) IPO last year. Although MindMed stock is available on foreign exchanges, this is the first time the company is trading on the U.S. markets.
Here’s everything you need to know…
MindMed IPO: The Business
MindMed is a clinical-stage psychedelic medicine and therapy company. It discovers and develops medicines to help patients with mental illnesses and addictions. This includes anxiety and ADHD.
On its website, the company shows the different phases its clinical trials are in. It …read more
